Calls
6
#1037
Alpha Score 9.7
Uhm Min-hyung
Pharmaceutical/Bio Analyst
Win Rate
0.0%
return
-16.8%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jun 25
$59200.00
-5.9%
Hanall Biopharma is a preferred name after achieving world-first clinical success in a difficult rheumatoid arthritis indication, setting the stage for additional lucrative licensing deals.
Pharma & Biotech
Long
Jun 25
$187700.00
-0.7%
Peptron is a preferred name as its long-acting obesity treatment partnership with Eli Lilly is expected to move toward a definitive agreement, providing a large deal catalyst.
GLP-1 / Obesity
Long
Jun 25
$158200.00
-27.7%
LegoChem Bio is a preferred name with an upcoming official release of clinical results for its ADC asset LCB84, which could act as a near-term catalyst.
Pharma & Biotech
Long
Jun 25
$384000.00
-17.3%
Alteogen is the sector top pick. It won a patent nullification suit against Halozyme, removing uncertainty, and became the first Korean biotech to sign two technology transfer deals in a single quarter with GSK and Biogen, proving its platform value and dealmaking capability.
Pharma & Biotech
Long
Jun 25
$144400.00
-18.3%
Olix is viewed as the second-best biotech after Alteogen. Its cosmetics commercialization with L'Oréal will generate revenue that can self-fund clinical development without additional capital raises, transforming it into a self-sustaining R&D company.
Pharma & Biotech
Long
Jun 25
$87200.00
-30.6%
DND Pharmatech's MASH treatment candidate demonstrated statistical significance across all three endpoints including fibrosis improvement, where Boehringer Ingelheim previously failed. This scientific edge makes a large-scale technology transfer highly likely.
GLP-1 / Obesity
Showing 6 of 6 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Uhm Min-hyung has 6 trade ideas tracked on Buzzberg across 6 tickers since June 2026. Ranked #1037 on the Buzzberg Alpha leaderboard. Most covered: 196170.KQ, 141080.KQ, 226950.KQ.
